186 related articles for article (PubMed ID: 36638328)
1. KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.
Qiu H; Makarov V; Bolzenius JK; Halstead A; Parker Y; Wang A; Iyer GV; Wise H; Kim D; Thayaparan V; Lindner DJ; Haber GP; Ting AH; Ren B; Chan TA; Arora V; Solit DB; Lee BH
Cancer Res; 2023 Mar; 83(6):814-829. PubMed ID: 36638328
[TBL] [Abstract][Full Text] [Related]
2. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
[TBL] [Abstract][Full Text] [Related]
3. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Liu L; Cui J; Zhao Y; Liu X; Chen L; Xia Y; Wang Y; Chen S; Sun S; Shi B; Zou Y
Mol Cancer; 2021 May; 20(1):77. PubMed ID: 34006303
[TBL] [Abstract][Full Text] [Related]
4. Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines.
Özden-Yılmaz G; Savas B; Bursalı A; Eray A; Arıbaş A; Senturk S; Karaca E; Karakülah G; Erkek-Ozhan S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980177
[TBL] [Abstract][Full Text] [Related]
5. X chromosome protects against bladder cancer in females via a
Kaneko S; Li X
Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
[TBL] [Abstract][Full Text] [Related]
6. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Revia S; Seretny A; Wendler L; Banito A; Eckert C; Breuer K; Mayakonda A; Lutsik P; Evert M; Ribback S; Gallage S; Chikh Bakri I; Breuhahn K; Schirmacher P; Heinrich S; Gaida MM; Heikenwälder M; Calvisi DF; Plass C; Lowe SW; Tschaharganeh DF
Gut; 2022 Aug; 71(8):1613-1628. PubMed ID: 34509979
[TBL] [Abstract][Full Text] [Related]
7.
Kobatake K; Ikeda KI; Nakata Y; Yamasaki N; Ueda T; Kanai A; Sentani K; Sera Y; Hayashi T; Koizumi M; Miyakawa Y; Inaba T; Sotomaru Y; Kaminuma O; Ichinohe T; Honda ZI; Yasui W; Horie S; Black PC; Matsubara A; Honda H
Clin Cancer Res; 2020 Apr; 26(8):2065-2079. PubMed ID: 32047002
[TBL] [Abstract][Full Text] [Related]
8. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Tran N; Broun A; Ge K
Mol Cell Biol; 2020 Sep; 40(20):. PubMed ID: 32817139
[TBL] [Abstract][Full Text] [Related]
9. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
Biochem Biophys Res Commun; 2017 Sep; 490(4):1407-1413. PubMed ID: 28698146
[TBL] [Abstract][Full Text] [Related]
11. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D
Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064
[TBL] [Abstract][Full Text] [Related]
12. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
[TBL] [Abstract][Full Text] [Related]
13. Significance of KDM6A mutation in bladder cancer immune escape.
Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
[TBL] [Abstract][Full Text] [Related]
14. MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Biswas M; Chatterjee SS; Boila LD; Chakraborty S; Banerjee D; Sengupta A
FASEB J; 2019 Apr; 33(4):5268-5286. PubMed ID: 30668141
[TBL] [Abstract][Full Text] [Related]
15. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
[TBL] [Abstract][Full Text] [Related]
16. Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Leng X; Wang J; An N; Wang X; Sun Y; Chen Z
Oncogene; 2020 Oct; 39(41):6468-6479. PubMed ID: 32879445
[TBL] [Abstract][Full Text] [Related]
17. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
Barrows D; Feng L; Carroll TS; Allis CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
[TBL] [Abstract][Full Text] [Related]
18. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages.
Li X; Zhang Q; Shi Q; Liu Y; Zhao K; Shen Q; Shi Y; Liu X; Wang C; Li N; Ma Y; Cao X
J Autoimmun; 2017 Jun; 80():85-94. PubMed ID: 28284523
[TBL] [Abstract][Full Text] [Related]
19. Kdm6a suppresses the alternative activation of macrophages and impairs energy expenditure in obesity.
Chen J; Xu X; Li Y; Li F; Zhang J; Xu Q; Chen W; Wei Y; Wang X
Cell Death Differ; 2021 May; 28(5):1688-1704. PubMed ID: 33303977
[TBL] [Abstract][Full Text] [Related]
20. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Lee SW; Park DY; Kim MY; Kang C
Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
